NMS 1116354

Drug Profile

NMS 1116354

Alternative Names: NMS-1116354; NMS-354; PHA-767491

Latest Information Update: 05 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nerviano Medical Sciences
  • Class Antineoplastics; Piperidones; Pyrroles; Small molecules
  • Mechanism of Action CDC7 protein kinase inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 05 Feb 2013 Discontinued - Phase-I for Solid tumours in France (PO)
  • 05 Feb 2013 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 16 Nov 2010 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top